Clinical assessment and treatment of attention deficit hyperactivity disorder in adults (Q36198624)

12 August 2017

1 reference

title

Clinical assessment and treatment of attention deficit hyperactivity disorder in adults (English)

1 reference

attention deficit hyperactivity disorder

12 August 2017

1 reference

1 reference

Philip Asherson

1

1 reference

PubMed ID

16026236

12 August 2017

language of work or name

1 reference

1 July 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

4

1 reference

12 August 2017

525-539

1 reference

Attention-Deficit Hyperactivity Disorder in the post-genomic era.

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Attention-deficit/hyperactivity disorder in adults: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Hyperactivity and conduct problems as risk factors for adolescent development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Gender and comorbid psychopathology in adolescents with alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

A prospective follow-up study of pediatric bipolar disorder in boys with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Is there a relationship between attention deficit hyperactivity disorder and bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.4.525

21 January 2018

Identifiers

DOI

10.1586/14737175.5.4.525

1 reference

12 August 2017

1 reference

PubMed ID

16026236